Family-owned Weaver Bros. of Alaska sells off majority stake in business
THE SO WHAT
A family-owned Alaska carrier selling a majority stake to Afognak Commercial Group to deepen energy and logistics exposure shows consolidation pressure even at regional edges of the supply chain. If you rely on niche transport partners, revisit concentration risk and pricing assumptions as more of these assets roll into larger portfolios.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechOwkin alum raises $25m seed to build world model for human cells
A $25M seed for a cellular “world model” is another data point that foundation-model logic is moving into wet biology. If you’re in drug discovery or tools, assume preclinical search space is going to be increasingly model-first and start mapping where your proprietary data actually compounds.
Deep & Emerging TechFederal Quantum Readiness Falls Short as Agencies Face Cryptography Skills Gaps
GAO finding that none of 24 major federal agencies have fully prepped for post-quantum cryptography is a clear lag indicator—public systems will be vulnerable longer than the math requires. If you run critical infrastructure or handle regulated data, don’t wait for federal timelines; start inventorying crypto dependencies and lining up PQC migration plans now.
Deep & Emerging TechApollo’s Wassenaar Sees Underinvestment Risk in AI Buildout
When an infra allocator that just deployed $20B+ in a quarter says AI buildout may be underinvested, the constraint is shifting from capital availability to project origination and execution. Operators depending on external AI capacity should treat power, gas processing, and data center lead times as strategic risks, not background assumptions.
Deep & Emerging TechMeta, Google DeepMind, and Isomorphic Labs invest $300M and the US invests $500M+ in Zuckerberg-backed Biohub to build open biology datasets for AI training
An ~$800M push into open biology datasets means the moat in AI-first drug discovery will lean harder on proprietary assays, models, and integration into pharma workflows — not just data access. If you’re building in bio+AI, assume foundational datasets commoditize and architect around speed to insight, regulatory alignment, and partnership depth.